MelanieBrandaburMD

Neurology • Sunnyvale, CA

Movement Disorder

Movement Disorders Neurologist UCSF Movement Disorders Department Medical Director Ultragenyx Pharmaceutical Inc

Join to view full profile

Dr. Brandabur is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brandabur's full profile

Already have an account?

Office
675 Almanor Ave
Sunnyvale, CA 94085
Phone+1 408-734-2800

Fax+1 408-734-8522

Education & Training

Rush University Medical CenterResidency, Neurology, 1988 - 1993
Ascension Illinois/Saint Joseph (Chicago)Internship, Internal Medicine, 1987 - 1988
Rush Medical College of Rush University Medical CenterClass of 1987

Certifications & Licensure

CA State Medical License 2006 - 2026
IL State Medical License 1987 - 2008
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013

Clinical Trials

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Start of enrollment: 2009 Nov 01
Unknown status
Phase 4
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
Parkinson's Foundation Quality Improvement Initiative Start of enrollment: 2009 Jul 01
Completed
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Start of enrollment: 2017 Apr 19
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study.
Valentina De Giorgis, Kailash P Bhatia, Odile Boespflug-Tanguy, Domitille Gras, Adela Della Marina
Movement Disorders. 2024-08-01
11 citations
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.
Pasquale Striano, Stéphane Auvin, Abigail Collins, Rita Horvath, Ingrid E Scheffer
Epilepsia. 2022-07-01
2 citations
Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency
Kristin Engelstad, Rachel Salazar, Dorcas Koenigsberger, Erin Stackowtiz, Susan Brodlie
Annals of Clinical and Translational Neurology. 2021-05-01

Professional Memberships

American Academy of Neurology - AAN
Member

Other Languages

French